Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Friedman HS, et al. Among authors: vredenburgh j. J Clin Oncol. 2009 Oct 1;27(28):4733-40. doi: 10.1200/JCO.2008.19.8721. Epub 2009 Aug 31. J Clin Oncol. 2009. PMID: 19720927 Corrected and republished. Clinical Trial.
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Wefel JS, et al. Among authors: vredenburgh j. Neuro Oncol. 2011 Jun;13(6):660-8. doi: 10.1093/neuonc/nor024. Epub 2011 May 9. Neuro Oncol. 2011. PMID: 21558074 Free PMC article. Clinical Trial.
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study.
Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Lada P, Prados M, Goldin J, Wen PY, Cloughesy T. Pope WB, et al. Among authors: vredenburgh j. J Neurooncol. 2012 Jul;108(3):491-8. doi: 10.1007/s11060-012-0847-y. Epub 2012 Mar 18. J Neurooncol. 2012. PMID: 22426926 Free PMC article.
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.
Affronti ML, Jackman JG, McSherry F, Herndon JE 2nd, Massey EC Jr, Lipp E, Desjardins A, Friedman HS, Vlahovic G, Vredenburgh J, Peters KB. Affronti ML, et al. Among authors: vredenburgh j. Oncologist. 2018 Aug;23(8):889-e98. doi: 10.1634/theoncologist.2018-0149. Epub 2018 Apr 17. Oncologist. 2018. PMID: 29666296 Free PMC article. Clinical Trial.
Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study.
Brenner AJ, Peters KB, Vredenburgh J, Bokstein F, Blumenthal DT, Yust-Katz S, Peretz I, Oberman B, Freedman LS, Ellingson BM, Cloughesy TF, Sher N, Cohen YC, Lowenton-Spier N, Rachmilewitz Minei T, Yakov N, Mendel I, Breitbart E, Wen PY. Brenner AJ, et al. Among authors: vredenburgh j. Neuro Oncol. 2020 May 15;22(5):694-704. doi: 10.1093/neuonc/noz231. Neuro Oncol. 2020. PMID: 31844886 Free PMC article. Clinical Trial.
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Reardon DA, Quinn JA, Rich JN, Gururangan S, Vredenburgh J, Sampson JH, Provenzale JM, Walker A, Badruddoja M, Tourt-Uhlig S, Herndon JE 2nd, Dowell JM, Affronti ML, Jackson S, Allen D, Ziegler K, Silverman S, Bohlin C, Friedman AH, Bigner DD, Friedman HS. Reardon DA, et al. Among authors: vredenburgh j. Neuro Oncol. 2004 Apr;6(2):134-44. doi: 10.1215/s1152851703000413. Neuro Oncol. 2004. PMID: 15134628 Free PMC article. Clinical Trial.
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Vredenburgh J, Gururangan S, Provenzale JM, Walker A, Schweitzer H, Bigner DD, Tourt-Uhlig S, Herndon JE 2nd, Affronti ML, Jackson S, Allen D, Ziegler K, Bohlin C, Lentz C, Friedman HS. Quinn JA, et al. Among authors: vredenburgh j. Neuro Oncol. 2004 Apr;6(2):145-53. doi: 10.1215/S1152851703000498. Neuro Oncol. 2004. PMID: 15134629 Free PMC article. Clinical Trial.
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA, Quinn JA, Rich JN, Desjardins A, Vredenburgh J, Gururangan S, Sathornsumetee S, Badruddoja M, McLendon R, Provenzale J, Herndon JE 2nd, Dowell JM, Burkart JL, Newton HB, Friedman AH, Friedman HS. Reardon DA, et al. Among authors: vredenburgh j. Cancer. 2005 Oct 1;104(7):1478-86. doi: 10.1002/cncr.21316. Cancer. 2005. PMID: 16088964 Free article. Clinical Trial.
210 results